Premium
Coumarin‐Rasagiline Hybrids as Potent and Selective h MAO‐B Inhibitors, Antioxidants, and Neuroprotective Agents
Author(s) -
Matos Maria J.,
Herrera Ibatá Diana M.,
Uriarte Eugenio,
Viña Dolores
Publication year - 2020
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000018
Subject(s) - rasagiline , coumarin , neuroprotection , monoamine oxidase b , monoamine oxidase , chemistry , pharmacology , edaravone , biochemistry , stereochemistry , parkinson's disease , enzyme , medicine , disease , organic chemistry
The frequency, complexity and morbidity of neurodegenerative diseases make them a great challenge for nowadays medicine. Most of the treatments currently used for Parkinson's disease – the second most prevalent – are only symptomatic. Therefore, it is urgent to develop drugs that are able to act simultaneously on different targets, being able to stop neuronal death and promote the recovery of neuronal populations already affected. In this work, we studied the activity of a series of hybrid molecules, which combine the structure of both coumarin and an alkynylamine group inspired on rasagiline, as MAO inhibitors, antioxidants and neuroprotective agents. Half of the studied hybrids turned out to be selective monoamine oxidase B ( h MAO‐B) inhibitors in the low micro/nanomolar range, demonstrating that positions 3 (compounds 1–3 ) and 7 (compounds 8 and 10 ) of the coumarin scaffold are the most suitable for the incorporation of the alkynylamine chain. All the studied compounds proved to be capable of neutralizing free radicals (DPPH). Finally, the 4‐(but‐2‐yn‐1‐ylamino)coumarin ( 5 ) showed neuroprotective effects on glial cells and the 4‐methyl‐7‐(pent‐2‐yn‐1‐ylamino)coumarin ( 8 ) inhibited intraneuronal ROS production as well.